Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02245074
Other study ID # 2009/056/HP
Secondary ID 2009- A00774-53
Status Terminated
Phase N/A
First received October 15, 2010
Last updated September 17, 2014
Start date June 2010
Est. completion date August 2012

Study information

Verified date September 2014
Source University Hospital, Rouen
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

- Background: Infantile asthma is composed of various phenotypes, however the definition is still based on the clinics. Namely, the infants could be classified as transitory, peristent or late and persistent asthma. Some risk factors for the persistent asthma phenotype are recognized as atopy. However all peristent asthma are not related to atopy. Regarding the pathophysiology, little is known on airways inflammation in these infants, and the current data are mostly based on the BAL analyses, or on biopsies. Consequently, BLA and biopsies should be justified by the need of an indicated fiberbronchoscopy, and therefore limited to severe infantile asthma. Airway secretion could be also collected after hypertonic saline induction and chest physiotherapy. This method has been validated in the children, but has not in the younger.

- Aim : Analyses of cell profiles regarding the severity of infantile asthma.

- Methods : This descriptive study compared 3 groups of infants, the first with acute exacerbation, the second with uncontrolled asthma and the third with controlled asthma. Accounting 25% of failure, the number of 40 infants per groups has been calculated. The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended. Safety will be evaluated.

- Inclusion criteria : Any infants suffering of infantile asthma (at least 3 episodes of wheezing during the 2 first years of life), aged between 6-12months.Asthma control was evaluated on the last 4 weeks, allowing to classify the infants . Control asthma was aimed when neither exacerbation nor persistent symptoms were observed. Uncontrolled asthma was defined whether the infant presented any symptoms during the last 4 weeks. Exacerbation was defined as any acute symptoms, as cough, dyspnoea or wheezing.

- Feasibility : A preliminary study has been presented in the Vienna ERS congress.


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date August 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 6 Months to 3 Years
Eligibility Inclusion Criteria:

- Age between 6 and 36 mo.

- Ambulatory or hospitalized.

- With %SaO2 ³ 95%

- Parents information and non-opposition from the parents

Exclusion Criteria:

- Any underlying chronic disease

- Been given oral corticosteroid during the last four weeks

- Known adverse events with nebulized saline solution

- With cold during the 4 last weeks for the controled group.

- With %SaO2 < 95%

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Other:
Sputum induction
The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.

Locations

Country Name City State
France Pediatric Department Rouen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cell profiles Analysis regarding the severity of asthma as defined above. Day 1 No
See also
  Status Clinical Trial Phase
Completed NCT02141893 - Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial N/A